+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the efficacy and safety of orelabrutinib, a brain-penetrating BTK inhibitor, in people with Primary Progressive Multiple Sclerosis PPMS. This is a Phase 3, randomized, double-blind, parallel-group, multicenter study comparing orelabrutinib with a placebo. Approximately 705 participants aged 18 to 60 with documented disability progression will be enrolled globally. Participants will be randomly assigned in a 21 ratio to receive either oral orelabrutinib or a placebo. Treatment will last approximately 30 to 60 months, with a minimum duration of 12 months. The study includes two groups one receiving orelabrutinib and the other receiving placebo, both taken orally. Throughout the study, participants will undergo regular assessments including disability progression measurements confirmed over 12 and 24 weeks, MRI scans, and tests such as the 9-hole Peg Test and Timed 25-Foot Walk Test. Safety will be monitored continuously, and the primary outcome is time to confirmed disability progression over about 120 weeks. Participants will be followed up for up to 5 years to evaluate the treatment effects and safety.

Age: 18Years - 60YearsAll GendersPhase 3
83 locations
E

Actively Recruiting

Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.

Age: 18Years - 60YearsAll GendersPhase 3
90 locations
R

Actively Recruiting

Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
296 locations
E

Actively Recruiting

Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of RO7268489 as an add-on therapy to ocrelizumab in adults with progressive multiple sclerosis PMS. This phase II, multi-center, double-blind, placebo-controlled study aims to understand how RO7268489 affects disability progression and other clinical measures in PMS patients receiving ocrelizumab. The study is sponsored by Hoffmann-La Roche and involves randomized parallel groups. Participants will receive either one of three doses of RO7268489 or a matching placebo, each combined with ocrelizumab according to a predefined dosing schedule. After the double-blind treatment period, eligible participants may continue to receive open-label RO7268489 in an extension phase. The interventions involve drug administration per schedule alongside ongoing ocrelizumab treatment. During the study, participants will be monitored for up to approximately 110 weeks for disability progression and cognitive function using standardized tests and assessments. Researchers will measure brain volume changes, plasma levels of 2-arachidonoylglycerol and the study drug, and track adverse events including treatment discontinuations and suicidal ideation up to 5 years. This comprehensive monitoring includes clinical evaluations, imaging, and laboratory tests to assess safety and efficacy over the study and follow-up periods.

Age: 18Years - 60YearsAll GendersPhase 2
114 locations
M

Actively Recruiting

Researchers are conducting a pre-screening study to identify individuals who may qualify for Roche interventional studies focused on Alzheimers disease. This study aims to assess potential eligibility by evaluating specific biomarkers and cognitive performance, helping to select suitable participants for future clinical trials related to Alzheimers disease. Participants will undergo testing to measure the concentration of pTau217 in their blood and complete the International Shopping List Test ISLT to assess cognitive function. There is no active treatment or intervention instead, the study collects these measurements to determine potential trial eligibility. During the study, participants will have blood samples drawn and complete cognitive assessments using the ISLT. Researchers will focus on the pTau217 biomarker levels and cognitive scores as primary outcomes measured on the first day of participation. This screening process helps identify candidates for subsequent interventional Alzheimers disease trials. The study is planned to run until July 2035 and includes adults aged 50 to 90 years.

Age: 50Years - 90YearsAll GendersPhase 3
234 locations
E

Actively Recruiting

Researchers are evaluating a modified regimen of ublituximab for adults with relapsing multiple sclerosis RMS in this phase 3b study. The study aims to assess the medicines impact on brain lesions visible on MRI scans and its pharmacokinetics, particularly in participants who had limited benefit from prior anti-CD20 therapies. The trial includes three parts Part A is open-label and single-arm, Part B is randomized, double-blind, and placebo-controlled, and Part C is open-label and single-arm. Participants receive ublituximab through intravenous infusions, with dosing schedules varying by study part. In Part A, infusions occur on Day 1 of Week 1, Day 15 if applicable, and at Week 24. In Part B, participants receive either 600 mg ublituximab on Week 1 Day 1, placebo on Day 15, and 450 mg ublituximab at Week 24, or 150 mg ublituximab on Week 1 Day 1 followed by 450 mg on Day 15 and Week 24. Part C participants receive 150 mg on Week 1 Day 1 and 450 mg on Day 15 and Week 24. During the study, participants are monitored for changes in T1 Gadolinium-enhancing lesions on MRI from baseline to Week 48, infusion-related reactions, treatment satisfaction, and pharmacokinetics over 16 weeks. Safety and efficacy assessments include neurological stability, clinical exams, and questionnaires. The total study duration extends to at least 48 weeks, with detailed follow-up and monitoring to evaluate treatment impact and participant health.

Age: 18Years - 65YearsAll GendersPhase 3
51 locations